Literature DB >> 8740611

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems.

Henry McQuay1, Dawn Carroll, Andrew Moore.   

Abstract

The objective was to investigate the relationship between pain relief scores produced by placebo and by active interventions in randomised controlled trials (RCTs). Individual patient categorical pain relief scores from 5 placebo-controlled single-dose parallel-group RCTs in acute postoperative pain were used to calculate the percentage of the maximum possible pain relief score (%maxTOTPAR) for the different treatments. One hundred and thirty of the 525 patients in the 5 trials had a placebo. Individual patients' scores with placebo varied from 0 to 100% of the maximum possible pain relief. The proportion who obtained more than 50% of the maximum possible pain relief with placebo varied from 7% to 37% across the trials; with the active drugs the variation was from 5 to 63%. Mean placebo scores were related to the mean score for the active treatments in each study; the higher the mean active score, the higher the mean placebo score. This relationship disappeared when median values were used. Medical folklore has it that the amount of relief obtained with placebo is one-third of the maximum possible (and does not vary), and that one-third of patients respond to placebo. The results show that the amount of relief obtained with placebo varies considerably between patients, that 38% of patients obtained more than 10% of the maximum possible relief, and 16% obtained greater than 50%. In double-blind, randomised parallel-group studies of high quality placebo scores should not vary. Despite these conditions being met the placebo scores did vary. The previous explanation, of a relationship between the mean placebo scores and the mean scores for the active treatments was not supported.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740611     DOI: 10.1016/0304-3959(95)00116-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  28 in total

1.  Placebo effect and placebos: what are we talking about? Some conceptual and historical considerations.

Authors:  Ana Macedo; Magí Farré; Josep-E Baños
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

2.  [Physicians do not treat averages--but therapy responders!].

Authors:  C Maier; R Baron
Journal:  Schmerz       Date:  2012-02       Impact factor: 1.107

Review 3.  Placebo.

Authors:  H J McQuay; R A Moore
Journal:  Postgrad Med J       Date:  2005-03       Impact factor: 2.401

Review 4.  Tramadol for neuropathic pain in adults.

Authors:  Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

5.  Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials.

Authors:  Albert González-Barnadas; Octavi Camps-Font; Pablo Martín-Fatás; Rui Figueiredo; Cosme Gay-Escoda; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2019-04-23       Impact factor: 3.573

Review 6.  Vitamin D for the treatment of chronic painful conditions in adults.

Authors:  Sebastian Straube; Sheena Derry; Carmen Straube; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2015-05-06

Review 7.  Gabapentin for chronic neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; Rae F Bell; Andrew Sc Rice; Thomas Rudolf Tölle; Tudor Phillips; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-09

Review 8.  Vitamin D for the treatment of chronic painful conditions in adults.

Authors:  Sebastian Straube; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  [Clinical significance of the placebo effect].

Authors:  J Oeltjenbruns; M Schäfer
Journal:  Anaesthesist       Date:  2008-05       Impact factor: 1.041

10.  Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.

Authors:  R A Moore; O A Moore; S Derry; P M Peloso; A R Gammaitoni; H Wang
Journal:  Ann Rheum Dis       Date:  2009-04-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.